Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
5.11
-0.15 (-2.85%)
At close: Apr 1, 2026, 4:00 PM EDT
5.11
0.00 (0.00%)
After-hours: Apr 1, 2026, 4:10 PM EDT

Atossa Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
15.9613.514.0412.6111.31
Research & Development
21.1914.1217.3315.089.21
Other Operating Expenses
--1.71-2.99--
Total Operating Expenses
37.1425.9128.3927.6920.52
Operating Income
-37.14-27.62-31.38-27.69-20.52
Interest Income
2.384.054.340.880.01
Other Non-Operating Income (Expense)
-0.01-0.22-0.07-0.15-0.09
Total Non-Operating Income (Expense)
2.373.834.270.73-0.09
Pretax Income
-34.77-25.5-30.09-26.96-20.61
Net Income
-34.77-25.5-30.09-26.96-20.61
Net Income to Common
-34.77-25.5-30.09-26.96-20.61
Shares Outstanding (Basic)
98888
Shares Outstanding (Diluted)
98888
Shares Change (YoY)
2.63%-0.18%-0.43%8.27%934.13%
EPS (Basic)
-4.04-3.04-3.60-3.15-2.70
EPS (Diluted)
-4.04-3.04-3.60-3.15-2.70
Shares Outstanding
8.618.618.358.448.44
Free Cash Flow
-29.79-21.05-20.96-20.79-16.48
Free Cash Flow Per Share
-3.46-2.51-2.49-2.46-2.11
EBITDA
-37.13-27.6-31.35-27.68-20.5
EBIT
-37.14-27.62-31.38-27.69-20.52
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q